

INTRODUCING A PURE PLAY LIFE SCIENCES & DIAGNOSTICS COMPANY

Transaction Features

- Announces agreement with intention to divest the **Analytical, Food, and Enterprise Services businesses** to **New Mountain Capital** for a **total consideration of \$2.45 billion**, including \$2.3 billion in cash and **\$150 million of future contingent consideration**
- The PerkinElmer Life Sciences and Diagnostic business will adopt a **new name and brand** – details to be announced prior to closing
- Stock will continue to trade as PerkinElmer (PKI) until **ticker symbol change is made effective at closing**
- Expected to close in **1Q 2023**

“We will be a **pure-play, high growth, high margin Life Sciences & Diagnostics** company with unique scale. The Company’s increased financial strength will support **accelerated investment into attractive end markets** across science and disease, and drive **advanced research, discovery, and improve global health.**”



Prahlad Singh
President and Chief
Executive Officer,
PerkinElmer Inc.

Strategic Rationale

Creates a Faster Growing, Higher Margin Company with Scale

Increases Focus on Life Sciences and Diagnostics

Accelerates Innovation and Capital Deployment

Who We Are

LIFE SCIENCES


- ✓ Top-tier **pre-clinical research & discovery franchise**
- ✓ Attractive and expanded positions in **biologics and cell & gene therapy**
- ✓ Complete workflow coverage seamlessly integrated with **automation & informatics**

\$20B+ TAM

DIAGNOSTICS

- ✓ Leading solutions in **infectious disease & autoimmune markets**
- ✓ Continued leadership in **reproductive health workflows**
- ✓ Enhanced **'omics sample prep** market position

\$35B+ TAM



~11,000

Total Employees

~80%

Recurring Revenue

10%+

**Expected
Organic Growth**